安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Liso-Cel Deemed Cost-Effective as Second-Line Treatment for DLBCL
Liso-cel is cost-effective as second-line therapy for diffuse large B-cell lymphoma, according to researchers
- Data Support Liso-Cel for Relapsed or Refractory CLL SLL
New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL SLL
- Second-Line Liso-Cel Produces Durable CRs in LBCL Patients Not Eligible . . .
Final results from the PILOT trial support liso-cel as second-line therapy for patients with relapsed refractory LBCL who are not eligible for transplant
- CRS, ICANS Rare After 2 Weeks of CAR T-Cell Therapy
New-onset ICANS from days 8 to 14 after CAR T-cell infusion occurred in 9 3% of patients overall, 19% of axi-cel recipients, 9% of liso-cel recipients, and 1% of tisa-cel recipients (P < 0001)
- Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R R CLL SLL
A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL SLL The following
- Advances in Anti-CD20 Therapies for Relapsed or Refractory Large B-Cell . . .
Key Takeaways Glofitamab, odronextamab, and epcoritamab are anti-CD20 bispecific antibodies that simultaneously bind to malignant B cells and circulating T cells Epcoritamab, which was approved
- ASCO 2024: Advances in Lymphoma - Cancer Therapy Advisor
Trials presented at ASCO 2024 highlighted advances in Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and NK T-cell lymphoma
- Oncology Drug Approval Decisions Expected in May 2024
Liso-Cel for MCL PDUFA date: May 31, 2024 Bristol Myers Squibb is also seeking approval for liso-cel to treat relapsed or refractory MCL
|
|
|